EA201790721A1 - Инъекционный состав бупренорфина - Google Patents

Инъекционный состав бупренорфина

Info

Publication number
EA201790721A1
EA201790721A1 EA201790721A EA201790721A EA201790721A1 EA 201790721 A1 EA201790721 A1 EA 201790721A1 EA 201790721 A EA201790721 A EA 201790721A EA 201790721 A EA201790721 A EA 201790721A EA 201790721 A1 EA201790721 A1 EA 201790721A1
Authority
EA
Eurasian Patent Office
Prior art keywords
opioid
buprenorphine
treatment
controlled release
provides
Prior art date
Application number
EA201790721A
Other languages
English (en)
Other versions
EA033935B1 (ru
Inventor
Фредрик Тиберг
Маркус Йонссон
Иан Харвигссон
Original Assignee
Камурус Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52103459&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201790721(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Камурус Аб filed Critical Камурус Аб
Publication of EA201790721A1 publication Critical patent/EA201790721A1/ru
Publication of EA033935B1 publication Critical patent/EA033935B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение обеспечивает инъекционный жидкий состав с контролируемым высвобождением, содержащий: a) липидную матрицу с контролируемым высвобождением, содержащую по меньшей мере 50% триациллипидов; b) по меньшей мере один кислородсодержащий органический растворитель; c) по меньшей мере 16% по массе по меньшей мере одного активного агента, выбранного из бупренорфина и его солей, в расчете на свободное основание бупренорфина. В настоящем изобретении представлен также способ лечения боли, опиоидной поддерживающей терапии или лечения опиоидной зависимости посредством детоксикации и/или поддерживающей терапии, или лечения или профилактики симптомов отмены опиоидов и/или отмены кокаина, посредством инъекционного введения указанной жидкой композиции.
EA201790721A 2014-10-27 2015-10-27 Инъекционный состав бупренорфина EA033935B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1419091.2A GB201419091D0 (en) 2014-10-27 2014-10-27 Formulations
PCT/EP2015/074901 WO2016066655A1 (en) 2014-10-27 2015-10-27 Injectable buprenorphine formulation

Publications (2)

Publication Number Publication Date
EA201790721A1 true EA201790721A1 (ru) 2017-09-29
EA033935B1 EA033935B1 (ru) 2019-12-11

Family

ID=52103459

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790721A EA033935B1 (ru) 2014-10-27 2015-10-27 Инъекционный состав бупренорфина

Country Status (17)

Country Link
US (1) US20180015031A1 (ru)
EP (1) EP3212168A1 (ru)
JP (1) JP6768648B2 (ru)
KR (2) KR102541281B1 (ru)
CN (1) CN107205920B (ru)
AU (1) AU2015340661B2 (ru)
BR (1) BR112017008721A2 (ru)
CA (1) CA2964045C (ru)
CL (1) CL2017001024A1 (ru)
EA (1) EA033935B1 (ru)
GB (1) GB201419091D0 (ru)
IL (1) IL251413B2 (ru)
MX (1) MX2017005461A (ru)
MY (1) MY183540A (ru)
SG (1) SG11201703158WA (ru)
TW (1) TW201625250A (ru)
WO (1) WO2016066655A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2877155T3 (pl) 2012-07-26 2021-05-17 Camurus Ab Formulacje opioidowe
NZ731309A (en) 2014-11-07 2022-02-25 Indivior Uk Ltd Buprenorphine dosing regimens
HUE060906T2 (hu) * 2016-09-13 2023-04-28 Alar Pharmaceuticals Inc Nyújtott felszabadulású buprenorfin-készítmények
MX2019002999A (es) 2016-09-15 2019-07-18 Camurus Ab Formulaciones de analogo de prostaciclina.
JP7138626B2 (ja) 2016-09-27 2022-09-16 カムルス エービー アルキルアンモニウムｅｄｔａ塩を含む混合物及び製剤
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
WO2023020608A1 (zh) * 2021-08-20 2023-02-23 苏州恩华生物医药科技有限公司 一种包含塞纳布啡的药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1263760C (zh) * 2002-11-12 2006-07-12 财团法人奇美医院 新颖的丁丙诺啡酯衍生物及其制备方法，以及长效作用镇痛药学组合物
DE60224288T2 (de) * 2002-11-25 2009-04-16 Chi Mei Foundation Medical Center Buprenorphinesterderivate, Verfahren zu ihrer Herstellung, und langwirksame analgetische Arzneimittel
SG173326A1 (en) * 2004-06-04 2011-08-29 Camurus Ab Liquid depot formulations
MX2011000629A (es) * 2008-07-17 2011-04-26 Merial Ltd Formulaciones analgesicas inyectables de larga duracion para animales.
GB2513267B (en) * 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
PL2877155T3 (pl) * 2012-07-26 2021-05-17 Camurus Ab Formulacje opioidowe
CN103142458B (zh) * 2013-01-22 2015-09-09 莱普德制药有限公司 无成瘾性镇痛缓释递药系统的组方与制备方法

Also Published As

Publication number Publication date
IL251413B1 (en) 2023-01-01
SG11201703158WA (en) 2017-05-30
JP2017532354A (ja) 2017-11-02
MX2017005461A (es) 2018-01-17
CA2964045A1 (en) 2016-05-06
CA2964045C (en) 2023-03-07
BR112017008721A2 (pt) 2018-01-30
KR20230039767A (ko) 2023-03-21
KR20170072237A (ko) 2017-06-26
KR102541281B1 (ko) 2023-06-13
IL251413A0 (en) 2017-05-29
AU2015340661B2 (en) 2018-04-26
WO2016066655A1 (en) 2016-05-06
IL251413B2 (en) 2023-05-01
CN107205920A (zh) 2017-09-26
US20210308041A1 (en) 2021-10-07
EA033935B1 (ru) 2019-12-11
TW201625250A (zh) 2016-07-16
MY183540A (en) 2021-02-25
GB201419091D0 (en) 2014-12-10
JP6768648B2 (ja) 2020-10-14
US20180015031A1 (en) 2018-01-18
AU2015340661A1 (en) 2017-04-20
CN107205920B (zh) 2021-05-25
NZ730521A (en) 2023-11-24
EP3212168A1 (en) 2017-09-06
CL2017001024A1 (es) 2017-11-10

Similar Documents

Publication Publication Date Title
EA201790721A1 (ru) Инъекционный состав бупренорфина
CL2018003588A1 (es) Uso de inhibidores de miostatina y terapias de combinación.
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
CL2019001292A1 (es) Nuevos derivados de quinolina.
CL2015002529A1 (es) Compuestos de tetrahidropirrolotiazina
CL2016002753A1 (es) Composición conservante de la madera
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
MX2016004035A (es) Formulaciones de espiro-isoxazolina de accion prolongada.
BR112017006113A2 (pt) combinações sinérgicas de auristatina
CL2015000615A1 (es) Compuestos derivados de 4-amino-quinolinas, inhibidores de rip2 cinasa; composicion farmaceutica que los comprende; uso para el tratamiento de enfermedades tales como enfermedad de crohn, colitis ulcerativa o sindrome de blau.
NZ709985A (en) Nitroxyl donors with improved therapeutic index
MX2016011744A (es) Soluciones de buprenorfina de liberacion sostenida.
MX2017006709A (es) Agente para prevenir o mejorar sintomas causados por desequilibrio de las hormonas sexuales.
ECSP17059323A (es) Formulacion de combinacion de tesofensina y betabloqueante
MX2019002190A (es) Uso de pridopidina para tratar distonías.
WO2016094834A3 (en) A method for treating a complement mediated disorder caused by an infectious agent in a patient
BR112017004925A2 (pt) composição e método
CY1124016T1 (el) Φαρμακοτεχνικες μορφες οπιοειδων
BR112017023164A2 (pt) composto, e, método de prevenir e/ou tratar a esteato-hepatite não alcoólica em um indivíduo em necessidade do mesmo
BR112019005456A2 (pt) composição farmacêutica e método para tratamento de esteatose hepática não alcoólica
BR112019003131A2 (pt) processo para preparar micropartículas contendo acetato de glatirâmero
EA033769B9 (ru) Отселектированный амид -гидроксимасляной кислоты и его применения при лечении злоупотребления алкоголем
MX2016008968A (es) Compuestos organicos.
BR112018073556A2 (pt) medicamento e composição farmacêutica para a prevenção ou o tratamento da neuralgia trigeminal, método para prevenir ou tratar neuralgia trigeminal em um indivíduo, e, uso de um composto de carbamato .